---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-095769"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2022-08-30T23:59:59+00:00"
generated_at: "2026-06-23T19:21:35.605067+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio appoints Henry Hagopian III as CFO, replacing Jeff McGroarty who departs

## Summary
- Henry Hagopian III appointed CFO effective Aug 29, 2022; Jeff McGroarty departs to pursue other interests.
- Hagopian has 30 years of finance experience, most recently SVP Finance & Treasurer at Organogenesis (ORGO).
- Compensation includes $375,000 base salary, 35% target bonus, and 120,000 stock options at $11.55 exercise price.
- Company highlights advancement of lead drug buntanetap into Phase 3 trials for neurodegenerative diseases.

## SEC filing metadata
- accession: 0001104659-22-095769
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2022-08-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465922095769/0001104659-22-095769-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465922095769/tm2224778d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-095769
- JSON: https://secwatch.observer/filing/0001104659-22-095769.json
- Plain text: https://secwatch.observer/filing/0001104659-22-095769.txt

## Key facts
- Executive change
  Jeffrey McGroarty departed as Chief Financial Officer at Annovis Bio, Inc..
  - Action: left
  - Role: Chief Financial Officer
  source text: Mr. McGroarty will leave the Company to pursue other interests.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477845/000110465922095769/0001104659-22-095769-index.htm
- Executive change
  Henry Hagopian III was appointed as Chief Financial Officer at Annovis Bio, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On August 29, 2022, the Board of Directors of Annovis Bio, Inc. (the “Company”) appointed Henry Hagopian III, age 54, as Chief Financial Officer of the Company, effective immediately, to replace Jeffrey McGroarty.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477845/000110465922095769/0001104659-22-095769-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.